Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ImmusanT start-up raises $20m to advance therapeutic vaccine for coeliac disease

This article was originally published in Scrip

Executive Summary

ImmusanT, a US biotech which was launched in March 2011 from research which originated in Australia, has raised $20 million in a series A round of financing from Vatera Healthcare Partners of New York. It is developing an immunotherapeutic vaccine that would treat coeliac disease akin to allergy shots whereby repeated doses are used for desensitisation. The startup is also developing a companion diagnostic and monitoring tool for coeliac disease.



Related Companies